Filing Flows › Comparisons › ABCL vs KYNB
AbCellera Biologics vs Kyntra Bio: ABCL and KYNB compared
AbCellera Biologics is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $3.7M for Kyntra Bio (Q1 2026). Kyntra Bio is growing faster (+36% against -76% a year earlier).
Where the money goes: ABCL and KYNB
AbCellera Biologics (ABCL) · Q2 2026
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
Kyntra Bio (KYNB) · Q1 2026
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
| AbCellera Biologics (ABCL) | Kyntra Bio (KYNB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $4.0M | $3.7M |
| Revenue growth, Y/Y | -76% | +36% |
| Operating margin | n/m | -369.7% |
| Net earnings | −$55.4M | −$15.2M |
| Net margin | — | -406.6% |
| Operating cash flow | $25.9M | −$13.9M |
| Free cash flow | $23.8M | — |
| Market value | $3.8B | — |
| Analysts’ mean target | $17.17 | — |
Where the revenue comes from
AbCellera Biologics
- Research fees: $3.9M (96%)
- Licensing and royalty revenue: $149K (4%)
Kyntra Bio
- Drug Product Revenue: $3.5M (93%)
- Development and Other Revenue: $246K (7%)
Questions
Which is bigger, AbCellera Biologics or Kyntra Bio?
AbCellera Biologics is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $3.7M for Kyntra Bio (Q1 2026).
Is AbCellera Biologics or Kyntra Bio growing faster?
Kyntra Bio is growing faster (+36% against -76% a year earlier).
More: AbCellera Biologics earnings · how AbCellera Biologics makes money · Kyntra Bio earnings · how Kyntra Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed May 12, 2026). Fiscal quarters can end on different dates. Not investment advice.